Clinical Trial Update: A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy [NA]

View source ↗

Summary

A pilot study sponsored by MD Anderson Cancer Center to evaluate if 18F-Fluciclovine (Axumin) PET-CT can differentiate true progression from pseudo-progression …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases

Drugs mentioned

• Axumin (fluciclovine F-18)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Brain Metastases | NA | Status: RECRUITING